

## Author Correction: Reverse engineering synthetic antiviral amyloids

Correction to: *Nature Communications*  
<https://doi.org/10.1038/s41467-020-16721-8>,  
published online 05 June 2020

<https://doi.org/10.1038/s41467-023-39293-9>

Published online: 13 June 2023



Check for updates

Emiel Michiels , Kenny Roose , Rodrigo Gallardo , Ladan Khodaparast, Laleh Khodaparast, Rob van der Kant , Maxime Siemons, Bert Houben , Meine Ramakers, Hannah Wilkinson, Patricia Guerreiro, Nikolaos Louros, Suzanne J. F. Kaptein , Lorena Itatí Ibañez , Anouk Smet, Pieter Baatsen, Shu Liu, Ina Vorberg , Guy Bormans, Johan Neyts, Xavier Saelens , Frederic Rousseau  & Joost Schymkowitz 

In this article the grant number G045920N relating to Funds for Scientific Research Flanders was omitted. The original article has been corrected.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023